Functional identification of cancer-specific methylation of CDO1, HOXA9, and TAC1 for the diagnosis of lung cancer

John Wrangle, Emi Ota Machida, Ludmila Danilova, Alicia Hulbert, Noreli Franco, Wei Zhang, Sabine C. Glöckner, Mathewos Tessema, Leander Van Neste, Hariharan Easwaran, Kornel E. Schuebel, Julien Licchesi, Craig M. Hooker, Nita Ahuja, Jun Amano, Steven A. Belinsky, Stephen B. Baylin, James G. Herman, Malcolm V. Brock

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Purpose: Non-small cell lung cancer (NSCLC) is the leading cause of cancer mortality in the world. Novel diagnostic biomarkers may augment both existing NSCLC screening methods as well as molecular diagnostic tests of surgical specimens to more accurately stratify and stage candidates for adjuvant chemotherapy. Hypermethylation of CpG islands is a common and important alteration in the transition from normal tissue to cancer. Experimental Design: Following previously validated methods for the discovery of cancer-specific hypermethylation changes, we treated eight NSCLC cell lines with the hypomethylating agent deoxyazacitidine or trichostatin A. We validated the findings using a large publicly available database and two independent cohorts of primary samples. Results: We identified >300 candidate genes. Using The Cancer Genome Atlas (TCGA) and extensive filtering to refine our candidate genes for the greatest ability to distinguish tumor from normal, we define a three-gene panel, CDO1, HOXA9, and TAC1, which we subsequently validate in two independent cohorts of primary NSCLC samples. This three-gene panel is 100% specific, showing no methylation in 75 TCGA normal and seven primary normal samples and is 83% to 99% sensitive for NSCLC depending on the cohort. Conclusion: This degree of sensitivity and specificity may be of high value to diagnose the earliest stages of NSCLC. Addition of this three-gene panel to other previously validated methylation biomarkers holds great promise in both early diagnosis andmolecular staging of NSCLC.

Original languageEnglish (US)
Pages (from-to)1856-1864
Number of pages9
JournalClinical Cancer Research
Volume20
Issue number7
DOIs
StatePublished - Apr 1 2014

Fingerprint

Non-Small Cell Lung Carcinoma
Methylation
Lung Neoplasms
Neoplasms
Atlases
Genes
trichostatin A
Biomarkers
Genome
CpG Islands
Molecular Pathology
Adjuvant Chemotherapy
Early Detection of Cancer
Routine Diagnostic Tests
Early Diagnosis
Research Design
Databases
Sensitivity and Specificity
Cell Line
Mortality

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Functional identification of cancer-specific methylation of CDO1, HOXA9, and TAC1 for the diagnosis of lung cancer. / Wrangle, John; Machida, Emi Ota; Danilova, Ludmila; Hulbert, Alicia; Franco, Noreli; Zhang, Wei; Glöckner, Sabine C.; Tessema, Mathewos; Van Neste, Leander; Easwaran, Hariharan; Schuebel, Kornel E.; Licchesi, Julien; Hooker, Craig M.; Ahuja, Nita; Amano, Jun; Belinsky, Steven A.; Baylin, Stephen B.; Herman, James G.; Brock, Malcolm V.

In: Clinical Cancer Research, Vol. 20, No. 7, 01.04.2014, p. 1856-1864.

Research output: Contribution to journalArticle

Wrangle, J, Machida, EO, Danilova, L, Hulbert, A, Franco, N, Zhang, W, Glöckner, SC, Tessema, M, Van Neste, L, Easwaran, H, Schuebel, KE, Licchesi, J, Hooker, CM, Ahuja, N, Amano, J, Belinsky, SA, Baylin, SB, Herman, JG & Brock, MV 2014, 'Functional identification of cancer-specific methylation of CDO1, HOXA9, and TAC1 for the diagnosis of lung cancer', Clinical Cancer Research, vol. 20, no. 7, pp. 1856-1864. https://doi.org/10.1158/1078-0432.CCR-13-2109
Wrangle, John ; Machida, Emi Ota ; Danilova, Ludmila ; Hulbert, Alicia ; Franco, Noreli ; Zhang, Wei ; Glöckner, Sabine C. ; Tessema, Mathewos ; Van Neste, Leander ; Easwaran, Hariharan ; Schuebel, Kornel E. ; Licchesi, Julien ; Hooker, Craig M. ; Ahuja, Nita ; Amano, Jun ; Belinsky, Steven A. ; Baylin, Stephen B. ; Herman, James G. ; Brock, Malcolm V. / Functional identification of cancer-specific methylation of CDO1, HOXA9, and TAC1 for the diagnosis of lung cancer. In: Clinical Cancer Research. 2014 ; Vol. 20, No. 7. pp. 1856-1864.
@article{2b5dcb353d984d04bfdb42044ac2c377,
title = "Functional identification of cancer-specific methylation of CDO1, HOXA9, and TAC1 for the diagnosis of lung cancer",
abstract = "Purpose: Non-small cell lung cancer (NSCLC) is the leading cause of cancer mortality in the world. Novel diagnostic biomarkers may augment both existing NSCLC screening methods as well as molecular diagnostic tests of surgical specimens to more accurately stratify and stage candidates for adjuvant chemotherapy. Hypermethylation of CpG islands is a common and important alteration in the transition from normal tissue to cancer. Experimental Design: Following previously validated methods for the discovery of cancer-specific hypermethylation changes, we treated eight NSCLC cell lines with the hypomethylating agent deoxyazacitidine or trichostatin A. We validated the findings using a large publicly available database and two independent cohorts of primary samples. Results: We identified >300 candidate genes. Using The Cancer Genome Atlas (TCGA) and extensive filtering to refine our candidate genes for the greatest ability to distinguish tumor from normal, we define a three-gene panel, CDO1, HOXA9, and TAC1, which we subsequently validate in two independent cohorts of primary NSCLC samples. This three-gene panel is 100{\%} specific, showing no methylation in 75 TCGA normal and seven primary normal samples and is 83{\%} to 99{\%} sensitive for NSCLC depending on the cohort. Conclusion: This degree of sensitivity and specificity may be of high value to diagnose the earliest stages of NSCLC. Addition of this three-gene panel to other previously validated methylation biomarkers holds great promise in both early diagnosis andmolecular staging of NSCLC.",
author = "John Wrangle and Machida, {Emi Ota} and Ludmila Danilova and Alicia Hulbert and Noreli Franco and Wei Zhang and Gl{\"o}ckner, {Sabine C.} and Mathewos Tessema and {Van Neste}, Leander and Hariharan Easwaran and Schuebel, {Kornel E.} and Julien Licchesi and Hooker, {Craig M.} and Nita Ahuja and Jun Amano and Belinsky, {Steven A.} and Baylin, {Stephen B.} and Herman, {James G.} and Brock, {Malcolm V.}",
year = "2014",
month = "4",
day = "1",
doi = "10.1158/1078-0432.CCR-13-2109",
language = "English (US)",
volume = "20",
pages = "1856--1864",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Functional identification of cancer-specific methylation of CDO1, HOXA9, and TAC1 for the diagnosis of lung cancer

AU - Wrangle, John

AU - Machida, Emi Ota

AU - Danilova, Ludmila

AU - Hulbert, Alicia

AU - Franco, Noreli

AU - Zhang, Wei

AU - Glöckner, Sabine C.

AU - Tessema, Mathewos

AU - Van Neste, Leander

AU - Easwaran, Hariharan

AU - Schuebel, Kornel E.

AU - Licchesi, Julien

AU - Hooker, Craig M.

AU - Ahuja, Nita

AU - Amano, Jun

AU - Belinsky, Steven A.

AU - Baylin, Stephen B.

AU - Herman, James G.

AU - Brock, Malcolm V.

PY - 2014/4/1

Y1 - 2014/4/1

N2 - Purpose: Non-small cell lung cancer (NSCLC) is the leading cause of cancer mortality in the world. Novel diagnostic biomarkers may augment both existing NSCLC screening methods as well as molecular diagnostic tests of surgical specimens to more accurately stratify and stage candidates for adjuvant chemotherapy. Hypermethylation of CpG islands is a common and important alteration in the transition from normal tissue to cancer. Experimental Design: Following previously validated methods for the discovery of cancer-specific hypermethylation changes, we treated eight NSCLC cell lines with the hypomethylating agent deoxyazacitidine or trichostatin A. We validated the findings using a large publicly available database and two independent cohorts of primary samples. Results: We identified >300 candidate genes. Using The Cancer Genome Atlas (TCGA) and extensive filtering to refine our candidate genes for the greatest ability to distinguish tumor from normal, we define a three-gene panel, CDO1, HOXA9, and TAC1, which we subsequently validate in two independent cohorts of primary NSCLC samples. This three-gene panel is 100% specific, showing no methylation in 75 TCGA normal and seven primary normal samples and is 83% to 99% sensitive for NSCLC depending on the cohort. Conclusion: This degree of sensitivity and specificity may be of high value to diagnose the earliest stages of NSCLC. Addition of this three-gene panel to other previously validated methylation biomarkers holds great promise in both early diagnosis andmolecular staging of NSCLC.

AB - Purpose: Non-small cell lung cancer (NSCLC) is the leading cause of cancer mortality in the world. Novel diagnostic biomarkers may augment both existing NSCLC screening methods as well as molecular diagnostic tests of surgical specimens to more accurately stratify and stage candidates for adjuvant chemotherapy. Hypermethylation of CpG islands is a common and important alteration in the transition from normal tissue to cancer. Experimental Design: Following previously validated methods for the discovery of cancer-specific hypermethylation changes, we treated eight NSCLC cell lines with the hypomethylating agent deoxyazacitidine or trichostatin A. We validated the findings using a large publicly available database and two independent cohorts of primary samples. Results: We identified >300 candidate genes. Using The Cancer Genome Atlas (TCGA) and extensive filtering to refine our candidate genes for the greatest ability to distinguish tumor from normal, we define a three-gene panel, CDO1, HOXA9, and TAC1, which we subsequently validate in two independent cohorts of primary NSCLC samples. This three-gene panel is 100% specific, showing no methylation in 75 TCGA normal and seven primary normal samples and is 83% to 99% sensitive for NSCLC depending on the cohort. Conclusion: This degree of sensitivity and specificity may be of high value to diagnose the earliest stages of NSCLC. Addition of this three-gene panel to other previously validated methylation biomarkers holds great promise in both early diagnosis andmolecular staging of NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=84898753633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898753633&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-13-2109

DO - 10.1158/1078-0432.CCR-13-2109

M3 - Article

C2 - 24486589

AN - SCOPUS:84898753633

VL - 20

SP - 1856

EP - 1864

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 7

ER -